- This addition collectively brings the Firm’s complete clinic depend to 16 globally, which incorporates presence in Colombia, Peru and the United Kingdom
- Peru represented 5% of the overall Latin America unit gross sales in 2021
- Within the second half of 2021, the Firm opened its first Zerenia™ clinic in Lima, in partnership with Clínica Montesur. Since opening the clinic, over 80% of the consults resulted in hashish prescriptions
- In August 2021, Khiron obtained registration of its first two medical hashish merchandise in Peru, out there on the market nationwide in late This autumn 2021
The partnership with CDL
As a specialised ache clinic, CDL already has ache administration specialists and a affected person base completely associated to persistent and acute ache. Beginning February 2022, Khiron will likely be leveraging the CDL’s present infrastructure and status to offer entry to cannabinoid-based therapies to a rising group of sufferers in Lima and surrounding areas.
Alvaro Torres, Khiron CEO and Director, commented, “In 2021, Peru represented round 5% of our complete quantity gross sales in Latin America, and now with our new partnership with CDL we consider we are able to improve our gross sales cost-effectively by increasing Zerenia™ in Peru. In our first clinic in Peru, over 80% of complete consultations resulted in medical hashish prescriptions, additional validating our distinctive, proof and service-driven technique. By establishing a brand new pain-focused partnership with CDL in Lima, we plan to develop past our present capability and provide completely different remedy alternate options to greater than 10,000 sufferers yearly. Khiron lately started inserting its registered merchandise in numerous drugstore channels throughout Peru, enhancing the convenience of entry to sufferers who’re prescribed medical hashish within the nation, and producing additional development. I’m very enthusiastic about this partnership because it additionally permits us to discover completely different enterprise fashions for the growth of Zerenia™ throughout the area and we look ahead to producing larger development within the Peruvian market with a inhabitants of over 32 million folks.”
About Khiron Life Sciences Corp.
Khiron is a number one international medical hashish firm with core operations in Latin America and Europe. Leveraging wholly-owned medical well being clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented strategy, doctor education schemes, scientific experience, product innovation, and give attention to creating accessto drive prescriptions and model loyalty with sufferers worldwide. The Firm has a gross sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to start gross sales in Mexico. The Firm is led by Co-founder and Chief Govt Officer, Alvaro Torres, along with an skilled and various govt crew and Board of Administrators.
Go to Khiron on-line at traders.khiron.ca
Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Ahead-Wanting Statements
This press launch might include sure “forward-looking info” and “forward-looking statements” inside the that means of relevant securities laws. All info contained herein that isn’t historic in nature might represent forward-looking info. Khiron undertakes no obligation to touch upon analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or monetary or working outcomes (as relevant). Though Khiron believes that the expectations mirrored in forward-looking statements on this press launch are cheap, such forward-looking assertion has been primarily based on expectations, elements and assumptions regarding future occasions which can show to be inaccurate and are topic to quite a few dangers and uncertainties, sure of that are past Khiron’s management, together with the chance elements mentioned in Khiron’s Annual Info Type which is on the market on Khiron’s SEDAR profile at www.sedar.com. The forward-looking info contained on this press launch is expressly certified by this cautionary assertion and is made as of the date hereof. Khiron disclaims any intention and has no obligation or accountability, besides as required by legislation, to replace or revise any forward-looking info, whether or not because of new info, future occasions or in any other case.
Neither the TSXV nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSXV) accepts accountability for the adequacy or accuracy of this press launch.
SOURCE Khiron Life Sciences Corp.
